BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas

Pathology

Volumn 46, Issue 1, 2014, Pages 79-80

  Farzin, Mahtab ^a,b   Toon, Christopher W ^b,c   Clarkson, Adele ^a,b   Sioson, Loretta ^a,b   Gill, Anthony J ^a,b,d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Histopath Pathology   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADENOMA; ANTIBODY SPECIFICITY; GENETICS; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LABORATORY DIAGNOSIS; MISSENSE MUTATION; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ADENOMA; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION, MISSENSE; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 84896776167     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000033     Document Type: Article

References (11)

1. Pakneshan S, Salajegheh A, Smith R.A., Lam AK-Y. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45: 346-56.
2. Capper D, Preusser M, Habel A., et al Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-9.
3. Skorokhod A, Capper D, von Deimling A, et al Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012; 67: 488-91.
4. Andrulis M, Penzel R, Weichert W., von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012; 36: 1796-1800.
5. Koperek O, Kornauth C, Capper D., et al Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36: 844-50.
6. Bullock M, O'Neill C, Chou A, et al Utilization of a MAB for BRAF V600E detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012; 19: 779-84.
7. Long GV, Wilmott JS, Capper D, et al Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61-5.
8. Toon CW, Walsh MD, Chou A, et al BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013; 37: 1592-602.
9. Preusser M, Capper D, Berghoff A.S., et al Expression of BRAF V600E mutant protein in epithelial ovarian tumours. Appl Immunohistochem Mol Morphol 2013; 21: 159-64.
10. Ilie M, Long E, Hofman V., et al Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013; 24: 742-8.
11. Sperveslage J, Gierke M, Capper D., et al VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol 2013; 125: 911-2.